...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Characteristics of the Drip-and-Ship Paradigm for Patients with Acute Ischemic Stroke in South Korea
【24h】

Characteristics of the Drip-and-Ship Paradigm for Patients with Acute Ischemic Stroke in South Korea

机译：韩国急性缺血性卒中患者的滴灌模式的特征

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Data on the drip-and-ship paradigm in Korea are limited. The present study aimed to evaluate the use of the drip-and-ship paradigm and the time delays and outcomes associated with the paradigm in Korea. Methods: We used data from the Clinical Research Center for Stroke-5 registry between January 2011 and March 2014. Among patients treated with tissue-type plasminogen activator (tPA), the use of the drip-and-ship paradigm was evaluated, and time delays and functional outcomes at 3 months were compared between patients treated with the paradigm and those treated directly at visits. Results: Among 1843 patients who met the eligibility criteria, 244 patients (13.2%) were treated with the drip-and-ship paradigm. Subsequent endovascular recanalization therapy was used in 509 patients (27.6%). The median time from symptom onset to groin puncture was greater in patients treated with the paradigm than in those treated directly at visits (305 versus 200 minutes, P < .001). In multivariate analysis, the risks of unfavorable functional outcomes and symptomatic intracranial hemorrhage were higher in ratio [OR] 2.15; 95% confidence interval [CI], 1.50-3.08; P < .001 and OR 1.78; 95% CI, 1.02-3.12; P = .041, respectively). Conclusions: In Korea, the drip-and-ship paradigm was used in less than 15% of all patients treated with tPA. The use of the paradigm might cause an increase in the onset-to-groin puncture time. Additionally, clinical outcomes might be worse in patients treated with the paradigm than in those treated directly at visits.
机译：背景：有关韩国的滴灌和运输范式的数据有限。本研究旨在评估滴灌和运输范式的使用以及与该范式相关的时间延迟和结果。方法：我们使用了2011年1月至2014年3月间的Stroke-5登记处临床研究中心的数据。在接受组织型纤溶酶原激活剂（tPA）治疗的患者中，评估了滴灌和运输范式的使用以及时间比较接受范式治疗的患者和直接就诊的患者在3个月时的延迟和功能结局。结果：在符合资格标准的1843名患者中，有244例（13.2％）患者接受了滴灌和运输范例治疗。 509例患者（27.6％）接受了随后的血管内再通治疗。接受范式治疗的患者从症状发作到腹股沟穿刺的中位时间比直接就诊的患者更长（305对200分钟，P <0.001）。在多变量分析中，不良的功能预后和有症状的颅内出血的风险比[OR] 2.15高; 95％置信区间[CI]，1.50-3.08; P <0.001和OR 1.78; 95％CI，1.02-3.12; P分别为.041）。结论：在韩国，tPA治疗的所有患者中只有不到15％使用了滴灌模式。使用范式可能会导致腹股沟穿刺时间的增加。此外，接受该范例治疗的患者的临床结局可能比直接就诊的患者更差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号